Frederik Desmarais1, Karl-F Bergeron1, Michel Lacaille2, Isabelle Lemieux3, Jean Bergeron4, Simon Biron3,5, Eric Rassart1, Denis R Joanisse2,3, Pascale Mauriege2,3, Catherine Mounier6. 1. BioMed Research Center, Department of Biological Sciences, University of Quebec in Montreal, Montreal, QC, Canada. 2. Department of Kinesiology, Faculty of Medicine, Laval University, Quebec City, QC, Canada. 3. Research Center of the Quebec University Heart and Lung Institute, Quebec City, QC, Canada. 4. Endocrinology and Nephrology Axis, Research Center of the University Hospital, Quebec City, QC, Canada. 5. Department of Surgery, Faculty of Medicine, Laval University, Quebec City, QC, Canada. 6. BioMed Research Center, Department of Biological Sciences, University of Quebec in Montreal, Montreal, QC, Canada. mounier.catherine@uqam.ca.
Abstract
PURPOSE: Apolipoprotein D (ApoD) is a lipocalin participating in lipid transport. It binds to a variety of ligands, with a higher affinity for arachidonic acid, and is thought to have a diverse array of functions. We investigated a potential role for ApoD in insulin sensitivity, inflammation, and thrombosis-processes related to lipid metabolism-in severely obese women. METHODS: We measured ApoD expression in a cohort of 44 severely obese women including dysmetabolic and non-dysmetabolic patients. Physical and metabolic characteristics of these women were determined from anthropometric measurements and blood samples. ApoD was quantified at the mRNA and protein levels in samples from three intra-abdominal adipose tissues (AT): omental, mesenteric and round ligament (RL). RESULTS: ApoD protein levels were highly variable between AT of the same individual. High ApoD protein levels, particularly in the RL depot, were linked to lower plasma insulin levels (-40%, p = 0.015) and insulin resistance (-47%, p = 0.022), and increased insulin sensitivity (+10%, p = 0.008). Lower circulating pro-inflammatory PAI-1 (-39%, p = 0.001), and TNF-α (-19%, p = 0.030) levels were also correlated to high ApoD protein in the RL AT. CONCLUSIONS: ApoD variability between AT was consistent with different accumulation efficiencies and/or metabolic functions according to the anatomic location of fat depots. Most statistically significant correlations implicated ApoD protein levels, in agreement with protein accumulation in target tissues. These correlations associated higher ApoD levels in fat depots with improved metabolic health in severely obese women.
PURPOSE:Apolipoprotein D (ApoD) is a lipocalin participating in lipid transport. It binds to a variety of ligands, with a higher affinity for arachidonic acid, and is thought to have a diverse array of functions. We investigated a potential role for ApoD in insulin sensitivity, inflammation, and thrombosis-processes related to lipid metabolism-in severely obesewomen. METHODS: We measured ApoD expression in a cohort of 44 severely obesewomen including dysmetabolic and non-dysmetabolicpatients. Physical and metabolic characteristics of these women were determined from anthropometric measurements and blood samples. ApoD was quantified at the mRNA and protein levels in samples from three intra-abdominal adipose tissues (AT): omental, mesenteric and round ligament (RL). RESULTS:ApoD protein levels were highly variable between AT of the same individual. High ApoD protein levels, particularly in the RL depot, were linked to lower plasma insulin levels (-40%, p = 0.015) and insulin resistance (-47%, p = 0.022), and increased insulin sensitivity (+10%, p = 0.008). Lower circulating pro-inflammatory PAI-1 (-39%, p = 0.001), and TNF-α (-19%, p = 0.030) levels were also correlated to high ApoD protein in the RL AT. CONCLUSIONS:ApoD variability between AT was consistent with different accumulation efficiencies and/or metabolic functions according to the anatomic location of fat depots. Most statistically significant correlations implicated ApoD protein levels, in agreement with protein accumulation in target tissues. These correlations associated higher ApoD levels in fat depots with improved metabolic health in severely obesewomen.
Authors: Michael D Jensen; Donna H Ryan; Caroline M Apovian; Jamy D Ard; Anthony G Comuzzie; Karen A Donato; Frank B Hu; Van S Hubbard; John M Jakicic; Robert F Kushner; Catherine M Loria; Barbara E Millen; Cathy A Nonas; F Xavier Pi-Sunyer; June Stevens; Victor J Stevens; Thomas A Wadden; Bruce M Wolfe; Susan Z Yanovski; Harmon S Jordan; Karima A Kendall; Linda J Lux; Roycelynn Mentor-Marcel; Laura C Morgan; Michael G Trisolini; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Marziyeh Salami; Ahmad Reza Bandegi; Hamid Reza Sameni; Abbas Ali Vafaei; Abbas Pakdel Journal: Neurochem Res Date: 2019-08-14 Impact factor: 3.996
Authors: Xiaoling Zhang; Jeroen G J van Rooij; Yoshiyuki Wakabayashi; Shih-Jen Hwang; Yanqin Yang; Mohsen Ghanbari; Daniel Bos; Daniel Levy; Andrew D Johnson; Joyce B J van Meurs; Maryam Kavousi; Jun Zhu; Christopher J O'Donnell Journal: BMC Med Genomics Date: 2021-02-10 Impact factor: 3.063